Biotech giant Celgene, who already owns a 9.7% stake in Juno announced this week that it will be acquiring Juno Therapeutics in a deal valued at $9 billion. The company will be acquiring the 90% stake that is left in the company and is paying roughly $87 a share to get it. Juno is known … Continue reading “Celgene to Acquire Juno Therapeutics for $9 Billion”
